Frankfurt - Delayed Quote EUR

Capricor Therapeutics, Inc. (4LN2.F)

14.40

+0.96

+(7.14%)

As of 3:29:02 PM GMT+1. Market Open.

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share price...

Simply Wall St. 9 days ago

CAPR
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 15 days ago

CAPR
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Zacks 28 days ago

CAPR

CSTL

SPRO
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission of its Biologics License Application (BLA) to the U.

GlobeNewswire 29 days ago

CAPR
High Growth Tech Stocks To Watch In December 2024

The United States market has remained flat over the last week but is up 29% over the past year, with earnings expected to grow by 15% per annum. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation while aligning with broader market trends.

Simply Wall St. last month

UI

ACAD

CAPR
Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences. Event:Piper Sandler 36th Annual Healthcare Conference (New York, NY)Presentation:Tuesday, December 3, 2024 from 11:30-11:55 a.m. ETFormat:Fireside chat, industry panel and one-on-one meeting

GlobeNewswire last month

CAPR
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European regionSAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency (EMA) has granted both Orphan Drug and Advanced Therapy Medicinal Product (ATMP) designation

GlobeNewswire 2 months ago

CAPR
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other best multibagger stocks. November has been an eventful month so far for the market as the Fed cut rates by a […]

Insider Monkey 2 months ago

CAPR
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Capricor Therapeutics ( NASDAQ:CAPR ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.26m (down 63% from...

Simply Wall St. 2 months ago

CAPR
Q3 2024 Capricor Therapeutics Inc Earnings Call

Q3 2024 Capricor Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

CAPR
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of -11.76% and 43.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CAPR
Capricor: Q3 Earnings Snapshot

SAN DIEGO (AP) — Capricor Therapeutics Inc. CAPR) on Wednesday reported a loss of $12.6 million in its third quarter. The San Diego-based company said it had a loss of 38 cents per share.

Associated Press Finance 2 months ago

CAPR
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Announced intent to file a biologics license application (BLA) for deramiocel to treat all patients with DMD-cardiomyopathy Rolling BLA submission initiated in October 2024 with full submission expected by year-end 2024Company anticipates potential PDUFA date in second half of 2025Announced signing of binding term sheet with Nippon Shinyaku for European expansion and commercialization of deramiocel; potential milestones from combined agreements would total approximately $1.5 billion payable to C

GlobeNewswire 2 months ago

CAPR
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

-Abstract Highlights New Preclinical Data on Exosome-Based Delivery of PMOs for the Treatment of DMD-SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX™ exosome platform technology is being presented at the 2024 American Associ

GlobeNewswire 2 months ago

CAPR
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

Zacks 2 months ago

CAPR
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 0% and 0.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

CAPR
Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Verano Holdings Corp. (VRNOF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

CAPR
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

CAPR

ICUI
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

Company to Host Conference Call, November 13, 2024 at 4:30 p.m. ETSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the third quarter ended September 30, 2024, after the market close on Wednesday, November 13, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on November 13. Ti

GlobeNewswire 2 months ago

CAPR
High Growth Tech Stocks to Watch in October 2024

The United States market has remained flat over the past week but has seen a significant 40% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability, aligning with these promising market conditions.

Simply Wall St. 3 months ago

CAPR

HUMA

HUMAW

Performance Overview

Return	4LN2.F	S&P 500
YTD	+9.42%	+3.50%
1-Year	+290.24%	+24.14%
3-Year	+453.85%	+37.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Capricor Therapeutics, Inc. (4LN2.F)

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

High Growth Tech Stocks To Watch In December 2024

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?

Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Q3 2024 Capricor Therapeutics Inc Earnings Call

Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates

Capricor: Q3 Earnings Snapshot

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?

Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates

Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?

Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

High Growth Tech Stocks to Watch in October 2024

Performance Overview